Wall Street Zen lowered shares of Momentus (NASDAQ:MNTS – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Momentus in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.
Get Our Latest Research Report on MNTS
Momentus Stock Down 4.3%
Momentus (NASDAQ:MNTS – Get Free Report) last issued its quarterly earnings data on Tuesday, August 19th. The company reported ($1.23) earnings per share for the quarter. The company had revenue of $0.19 million for the quarter.
Institutional Investors Weigh In On Momentus
An institutional investor recently raised its position in Momentus stock. Armistice Capital LLC grew its holdings in shares of Momentus Inc. (NASDAQ:MNTS – Free Report) by 21.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 264,227 shares of the company’s stock after buying an additional 46,968 shares during the period. Armistice Capital LLC owned approximately 5.03% of Momentus worth $528,000 as of its most recent filing with the SEC. 9.24% of the stock is owned by institutional investors and hedge funds.
Momentus Company Profile
Momentus Inc, together with its subsidiaries, operates as a commercial space company. The company focuses on providing in-space infrastructure services, including in-space transportation, hosted payloads, and in-orbit services. Its principal and target customers include satellite operators. The company is headquartered in San Jose, California.
Featured Articles
- Five stocks we like better than Momentus
- How to Invest in Blue Chip Stocks
- 4 Cold-Weather Stocks to Buy as Winter Spending Heats Up
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?
- What Are Earnings Reports?
- Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?
Receive News & Ratings for Momentus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momentus and related companies with MarketBeat.com's FREE daily email newsletter.
